Literature DB >> 1926189

Chymotrypsin treatment increases the activity of Clostridium perfringens enterotoxin.

P E Granum1, M Richardson.   

Abstract

Chymotrypsin treatment of the enterotoxin from Clostridium perfringens results in the loss of 36 amino acids from the N-terminus and 3 amino acids from the C-terminus. This processing results in a 3.2 fold increase in activity on Vero cells, which is close to what had been found for trypsin treatment following the loss of 25 amino acids from the N-terminus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1926189     DOI: 10.1016/0041-0101(91)90227-i

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

1.  Identification of a Clostridium perfringens enterotoxin region required for large complex formation and cytotoxicity by random mutagenesis.

Authors:  J F Kokai-Kun; K Benton; E U Wieckowski; B A McClane
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

2.  Native or Proteolytically Activated NanI Sialidase Enhances the Binding and Cytotoxic Activity of Clostridium perfringens Enterotoxin and Beta Toxin.

Authors:  James R Theoret; Jihong Li; Mauricio A Navarro; Jorge P Garcia; Francisco A Uzal; Bruce A McClane
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

3.  Fine mapping of the N-terminal cytotoxicity region of Clostridium perfringens enterotoxin by site-directed mutagenesis.

Authors:  James G Smedley; Bruce A McClane
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

Review 4.  The interaction of Clostridium perfringens enterotoxin with receptor claudins.

Authors:  Archana Shrestha; Francisco A Uzal; Bruce A McClane
Journal:  Anaerobe       Date:  2016-04-16       Impact factor: 3.331

Review 5.  Specificity of interaction between clostridium perfringens enterotoxin and claudin-family tight junction proteins.

Authors:  Leslie A Mitchell; Michael Koval
Journal:  Toxins (Basel)       Date:  2010-06-24       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.